Is endogenous erythropoietin a pathogenetic factor in the development of essential hypertension?

Nephrology Dialysis Transplantation

Volumn 12, Issue 6, 1997, Pages 1155-1160

  Langenfeld, M R W ^a   Veelken, R ^a   Schobel, H P ^a   Friedrich, A ^a   Schmieder, R E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Erythropoietin; Essential hypertension; Renal haemodynamics

Indexed keywords

4 AMINOHIPPURIC ACID; ERYTHROPOIETIN; HEMOGLOBIN; INULIN;

ADULT; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; BORDERLINE HYPERTENSION; CELL PROLIFERATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOGRAPHY; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; HEMATOCRIT; HEMODYNAMICS; HEMOGLOBIN DETERMINATION; HUMAN; INULIN CLEARANCE; KIDNEY BLOOD FLOW; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; VASOCONSTRICTION;

ADULT; BLOOD PRESSURE; ERYTHROPOIETIN; HEMATOCRIT; HEMODYNAMIC PROCESSES; HEMOGLOBINS; HUMANS; HYPERTENSION; MIDDLE AGED; RENAL CIRCULATION; RENAL PLASMA FLOW;

EID: 0030905659     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.6.1155     Document Type: Article

References (27)

1. Messerli FH. De Cavalho JGR, Christie B, Frohlich ED. Systemic and regional hemodynamics in low, normal and high cardiac output borderline hypertension. Circulation 1978; 58: 441-448
2. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 1990; 300: 573-578
3. Sundahl E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin. Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989; 4: 979-987
4. Hori K, Onoyama K, Iseki K, Fujimi S, Fujishima M. Hemodynamic and volume changes by human recombinant erythropoietin (rHuEPO) in the treatment of anaemic hemodialysis patients. Clin Nephrol 1990; 33: 293-298
5. Satoh K, Masuda T, Ikeda Y et al. Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients. Hypertension 1990; 15: 262-266
6. Samtleben W, Baldamus CA, Bommer J, Fassbinder W, Nonnast-Daniel B, Gurland HJ. Blood pressure changes during treatment with recombinant human erythropoietin. Contrib Nephrol 1988; 66: 114-122
7. Baskin S, Lasker N. Erythropoietin-associated hypertension [letter]. N Engl J Med 1990; 323: 999
8. Heidenreich S, Rahn K-H, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39: 259-265
9. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-5982
10. Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S. Genetic disposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med 1994; 94: 401-406
11. Gould AB, Goodman SA. Effect of an angiotensin-converting enzyme inhibitor on blood pressure and erythropoiesis in rats. Eur J Pharmacol 1990; 181: 225-234
12. Gatzka DG, Schmieder RE, Schobel HP, Klingbeil AU, Weihprecht H. Improved prediction of left ventricular mass from ambulatory blood pressure monitoring using average time-tension index. J Hypertens 1993; 11 [Suppl 5]: S98-S99
13. Cole RB, Giangiacomo J, Ingelfinger JR, Robsa AU. Measurement of renal function without urine collection. A critical evaluation of the constant-infusion-technique for determination of Inulin and Para-aminohippurate clearance. N Engl J Med 1972; 287: 1109-1114
14. Schmieder RE, Gatzka CE, Schobel HP, Schächinger H, Weihprecht H. Renal hemodynamic response to stress is influenced by ACE-inhibitors. Clin Nephrol 1994; 6: 381-388
15. Schmieder RE, Langenfeld MRW, Friedrich A, Schobel HP, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996; 94: 1304-1309
16. Sahn DF, de Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1080
17. Lewis JF, Kuo LC, Nelson JG, Limacher MC, Quinones MA. Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window. Circulation 1984; 70: 425-431
18. Garcia JF, Ebbe SN, Hollander L, Cutting HO, Miller ME, Cronkite EP. Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings. J Lab Clin Med 1982; 99: 624-635
19. Norusis MJI. SPSS. In: SPSS for Windows, Professional Statistics, Release 6.0, Chicago 1993
20. ++ mobilisation? Int Angiol 1994; 13: 75-77
21. Linde T, Sandhagen B, Hägg A, Mörlin C, Wikström B, Danielson BG. Blood viscosity and peripheral vascular resistance in patients with untreated essential hypertension. J Hypertens 1993; 11: 731-736
22. Nowicki M, Kokot F, Wiecek A. Influence of the renin-angiotensin system stimulation on erythropoietin production in patients with various forms of arterial hypertension. Nephron 1993; 65: 527-532
23. Bourgoignie JJ, Gallagher NI, Perry HM, Kurz L, Warnecke MA, Donati RM. Renin and erythropoietin in normotensive and in hypertensive patients. J Lab Clin Med 1968; March: 523-536
24. Perera GA. Hypertensive vascular disease: description and natural history. J Chron Dis 1955; 1: 33-42
25. Schmieder RE, Schachinger H, Messerli FH. Accelerated decline in renal perfusion with aging in essential hypertension. Hypertension 1994; 23: 351-357
26. Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995; 48: 806-813
27. Kokot M, Kokot F, Franek E, Wiecek A, Nowicki M, Dufawa J. Effect of isobaric hyperoxemia on erythropoietin secretion in hypertensive patients. Hypertension 1994; 24: 486-490